Search results for "immunosuppression"

showing 10 items of 240 documents

Patient outcomes in two steroid-free regimens using tacrolimus monotherapy after daclizumab induction and tacrolimus with mycophenolate mofetil in li…

2008

Introduction. Long-term steroid administration may predispose liver transplant recipients to infectious and metabolic complication. Maintaining effective immunoprophylaxis while minimizing the negative consequences of steroid therapy could be a key factor in improving clinical outcomes.Methods. Six hundred two patients were randomized to receive tacrolimus (TAC) immunosuppression with a single-steroid bolus and two doses of daclizumab (DAC) or mycophenolate mofetil (MMF).Results. The incidence of biopsy-proven acute rejection was 19.7% in the TAC/DAC group and 16.2% in the TAC/ MMF group (ns). Three-month patient and graft survival were similar. Steroid use at month-3 was low at 5.5% in the…

Graft RejectionLiver CirrhosisMaleDaclizumabmedicine.medical_treatment030230 surgeryLiver transplantationGastroenterology0302 clinical medicineDaclizumabAdrenal Cortex HormonesSafety outcomeAntibacterial agentLiver NeoplasmsAntibodies Monoclonal3. Good healthTreatment OutcomeAcute DiseaseCorticosteroid030211 gastroenterology & hepatologyDrug Therapy CombinationFemaleImmunosuppressive Agentsmedicine.drugAdultmedicine.medical_specialtymedicine.drug_classchemical and pharmacologic phenomenaAntibodies Monoclonal HumanizedMycophenolic acidTacrolimusABO Blood-Group System03 medical and health sciencesInternal medicinemedicineHumansTransplantationTacrolimus monotherapybusiness.industryPatient SelectionSteroid-free immunosuppressionMycophenolic AcidSurvival AnalysisTacrolimusSurgeryLiver TransplantationCalcineurinstomatognathic diseasesRegimenImmunoglobulin GbusinessTransplantation
researchProduct

HCV-induced immune responses influence the development of operational tolerance after liver transplantation in humans.

2014

Pathogen-induced immune responses prevent the establishment of transplantation tolerance in experimental animal models. Whether this occurs in humans as well remains unclear. The development of operational tolerance in liver transplant recipients with chronic hepatitis C virus (HCV) infection allows us to address this question. We conducted a clinical trial of immunosuppression withdrawal in HCV-infected adult liver recipients to elucidate (i) the mechanisms through which allograft tolerance can be established in the presence of an ongoing inflammatory response and (ii) whether anti-HCV heterologous immune responses influence this phenomenon. Of 34 enrolled liver recipients, drug withdrawal…

Graft RejectionMaleHepatitis C virusT cellmedicine.medical_treatmentHepacivirusLiver transplantationCD8-Positive T-Lymphocytesmedicine.disease_causeImmune systemInterferonmedicineImmune ToleranceHumansLymphocyte CountImmunosuppression Therapybusiness.industryImmunityImmunosuppressionReceptors Antigen T-Cell gamma-deltaGeneral MedicineMiddle Agedmedicine.diseaseLiver TransplantationTransplantationmedicine.anatomical_structureGene Expression RegulationImmunologyInterferon Type IFemaleViral hepatitisbusinessBiomarkersmedicine.drugScience translational medicine
researchProduct

First report on fertility after allogeneic uterus transplantation

2010

Uterus transplantation may become the first available treatment for uterine factor infertility, which is due to the absence or malfunction of the uterus. Here we describe for the first time pregnancy after allogeneic uterus transplantation, as a proof of concept of uterine function in a transplanted uterus in a standardized animal model (rat) under immunosuppression.

Graft RejectionMaleInfertilitymedicine.medical_specialtymedia_common.quotation_subjectmedicine.medical_treatmentUterusFertilityTacrolimusRats Sprague-DawleyAnimal modelPregnancyUterus transplantationmedicineAnimalsTransplantation Homologousmedia_commonGynecologyPregnancyurogenital systembusiness.industryUterusObstetrics and GynecologyImmunosuppressionGeneral Medicinemedicine.diseaseRatsTransplantationFertilitysurgical procedures operativemedicine.anatomical_structureRats Inbred LewFemalebusinessInfertility FemaleImmunosuppressive AgentsActa Obstetricia et Gynecologica Scandinavica
researchProduct

Hepatocellular carcinoma recurrence after acute liver allograft rejection treatment: A multicenter European experience

2019

During the last decades, several risk factors for the recurrence of hepatocellular carcinoma (HCC) after liver transplantation (LT) have been investigated. However, the impact of two important drivers of oncogenesis, namely the immunosuppression and the treatment of acute cellular rejection (ACR) have been marginally addressed. This study aimed at investigating the impact of ACR treatment on the incidence of tumor recurrence in a large European HCC-LT population. Seven hundred and eighty-one adult patients transplanted between February 1, 1985 and June 30, 2016 were retrospectively analyzed. After propensity score match, 116 patients treated for ACR using steroid boluses were compared with …

Graft RejectionMaleTime Factorsmedicine.medical_treatmentLiver transplantationGastroenterologyAcute rejection; Liver biopsy; Liver transplantation; Recurrence; Steroid0302 clinical medicineRisk FactorsRecurrenceProspective cohort studyeducation.field_of_studymedicine.diagnostic_testIncidenceIncidence (epidemiology)Liver NeoplasmsGastroenterologyImmunosuppressionMiddle AgedLiver biopsyAllograftsEuropeTreatment Outcome030220 oncology & carcinogenesisLiver biopsyHepatocellular carcinomaAcute rejectionFemaleSteroids030211 gastroenterology & hepatologyImmunosuppressive Agentsmedicine.medical_specialtyCarcinoma HepatocellularPopulationRisk Assessment03 medical and health sciencesInternal medicinemedicineHumanseducationSteroidRetrospective StudiesLiver transplantationHepatologybusiness.industrymedicine.diseaseLiver TransplantationTransplantationNeoplasm Recurrence LocalbusinessHepatobiliary & Pancreatic Diseases International
researchProduct

12-month follow-up analysis of a multicenter, randomized, prospective trial in de novo liver transplant recipients (LIS2T) comparing cyclosporine mic…

2006

The LIS2T study was an open-label, multicenter study in which recipients of a primary liver transplant were randomized to cyclosporine microemulsion (CsA-ME) (Neoral) (n = 250) (monitoring of blood concentration at 2 hours postdose) C2 or tacrolimus (n = 245) (monitoring of trough drug blood level [predose]) C0 to compare efficacy and safety at 3 and 6 months and to evaluate patient status at 12 months. All patients received steroids with or without azathioprine. At 12 months, 85% of CsA-ME patients and 86% of tacrolimus patients survived with a functioning graft (P not significant). Efficacy was similar in deceased- and living-donor recipients. Significantly fewer hepatitis C–positive pati…

Graft RejectionMaleTime Factorsmedicine.medical_treatmentTACROLIMUSAzathioprineHepacivirusHEPATITIS-CLiver transplantationmedicine.disease_causeGastroenterologychemistry.chemical_compoundLiving DonorsLongitudinal StudiesC-2IMMUNOSUPPRESSIONHEPATITIS-C DIABETES-MELLITUS C-2 REPLICATION RECURRENCE SURVIVALGraft SurvivalHepatitis CTreatment Outcomesurgical procedures operativeCreatinineSURVIVALEmulsionsFemaleSteroidsImmunosuppressive Agentsmedicine.drugmedicine.medical_specialtyHepatitis C virusRenal functionRANDOMIZED STUDYAge DistributionInternal medicinemedicineDiabetes MellitusHumansHypoglycemic AgentsRECURRENCEMonitoring PhysiologicHepatitisTransplantationCreatinineHepatologybusiness.industryLIVER TRANSPLANTATIONDIABETES-MELLITUSmedicine.diseaseSurvival AnalysisTacrolimusSurgerychemistryREPLICATIONCYCLOSPORINESurgerybusinessFollow-Up Studies
researchProduct

Obstetric and Neonatal Outcome of Pregnancies Fathered by Males on Immunosuppression After Solid Organ Transplantation

2015

Immunosuppressive drugs may influence spermatogenesis, but little is known about outcome of pregnancies fathered by transplanted males. We estimated risk of adverse outcomes in pregnancies (with data after the first trimester) fathered by males that had undergone organ transplantation and were treated with immunosuppression. A population-based study, linking data from the Norwegian transplant registry and the Medical Birth Registry of Norway during 1967-2009 was designed. All Norwegian men undergoing solid organ transplantation were included. Odds ratios for major malformations, preeclampsia, preterm delivery (<37 weeks) and small-for-gestational-age were obtained using logistic regression.…

Graft RejectionMaleimmunosuppressantmedicine.medical_treatmentOrgan transplantationCohort StudiesFathersPre-EclampsiaObstetrics and gynaecologyPregnancyRisk FactorsImmunology and AllergyPharmacology (medical)Registrieseducation.field_of_studyNorwayObstetricsPregnancy OutcomeImmunosuppressionMiddle Agedpracticesurgical procedures operativePremature BirthFemalepregnancyImmunosuppressive AgentsLung TransplantationAdultmedicine.medical_specialtyAdolescentPopulationCongenital AbnormalitiesPreeclampsiaYoung AdultmedicineHumansSpermatogenesiseducationRetrospective Studiesobstetrics and gynecologyTransplantationPregnancybusiness.industryOrgan TransplantationOdds ratiomedicine.diseasehealth services and outcomes researchKidney TransplantationLiver TransplantationSurgeryPregnancy ComplicationsTransplantationclinical researchHeart Transplantationbusiness
researchProduct

Improved Survival in Liver Transplant Patients Receiving Prolonged-release Tacrolimus-based Immunosuppression in the European Liver Transplant Regist…

2019

BACKGROUND: We compared, through the European Liver Transplant Registry, long-term liver transplantation outcomes with prolonged-release tacrolimus (PR-T) versus immediate-release tacrolimus (IR-T)-based immunosuppression. This retrospective analysis comprises up to 8-year data collected between 2008 and 2016, in an extension of our previously published study. METHODS: Patients with <1 month follow-up were excluded; patients were propensity score matched for baseline characteristics. Efficacy measures included: univariate/multivariate analyses of risk factors influencing graft/patient survival up to 8 years posttransplantation, and graft/patient survival up to 4 years with PR-T versus IR-T.…

Graft RejectionMalemedicine.medical_specialtyTime FactorsDrug Compoundingmedicine.medical_treatmentCalcineurin InhibitorsMedizinMEDLINEchemical and pharmacologic phenomenaLiver Transplant030230 surgeryLiver transplantationRisk AssessmentTacrolimusall contributing centers (www.eltr.org) and the European Liver and Intestine Transplant Association (ELITA)03 medical and health sciences0302 clinical medicineRisk FactorsProlonged releaseInternal medicinemedicineHumansAged; Calcineurin Inhibitors; Delayed-Action Preparations; Drug Compounding; Europe; Female; Graft Rejection; Graft Survival; Humans; Immunosuppressive Agents; Male; Middle Aged; Registries; Retrospective Studies; Risk Assessment; Risk Factors; Tacrolimus; Time Factors; Treatment Outcome; Liver TransplantationRegistriesAgedRetrospective StudiesTransplantationbusiness.industryGraft SurvivalImmunosuppressionRetrospective cohort studyMiddle AgedTacrolimusSettore MED/18Liver Transplantation3. Good healthEuropeTreatment Outcomesurgical procedures operativeDelayed-Action PreparationsFemale030211 gastroenterology & hepatologyTransplant patientbusinessRisk assessmentImmunosuppressive AgentsTransplantation
researchProduct

Hepatitis C virus re-infection: new perspectives

2006

Hepatitis C virus (HCV) re-infection of the liver graft has been recognized to be one of the most important factors that determines prognosis and outcome after liver transplantation in HCV-positive patients. Graft loss due to recurrent HCV re-cirrhosis and subsequent hepatic decompensation, which is the predominant cause of death among transplant recipients, reflects the prognostic significance of HCV re-infection. Despite better overall outcome after liver transplantation, the prognosis of HCV-infected patients has not improved during the last two decades. Recent data suggest that increased liver donor age and intensified immunosuppression of transplant patients are the most important cont…

Graft RejectionOncologymedicine.medical_specialtyCirrhosismedicine.medical_treatmentHepatitis C virusHepacivirusHepacivirusLiver transplantationmedicine.disease_causechemistry.chemical_compoundRecurrenceInternal medicinemedicineHumansCause of deathTransplantationbiologybusiness.industryRibavirinImmunosuppressionHepatitis C Chronicmedicine.diseasebiology.organism_classificationLiver TransplantationTransplantationchemistryImmunologybusinessClinical Transplantation
researchProduct

Results of heart retransplantation: subanalysis of the Spanish Heart Transplant Registry

2021

Heart retransplantation (ReHT) is controversial in the current era. The aim of this study was to describe and analyze the results of ReHT in Spain. Methods We performed a retrospective cohort analysis from the Spanish Heart Transplant Registry from 1984 to 2018. Data were collected on donors, recipients, surgical procedure characteristics, immunosuppression, and survival. The main outcome was posttransplant all-cause mortality or need for ReHT. We studied differences in survival according to indication for ReHT, the time interval between transplants and era of ReHT. Results A total of 7592 heart transplants (HT) and 173 (2.3%) ReHT were studied (median age, 52.0 and 55.0 years, respectively…

Graft RejectionReoperationmedicine.medical_specialtyTrasplante cardiacoSurvivalmedicine.medical_treatmentRetrasplante cardiacoEnfermedad cardiovascularCardiac allograft vasculopathyCold Ischemia TimeHeart retransplantation Heart transplant Retrasplante cardiaco Supervivencia Survival Trasplante cardiacoCirugíaInternal medicinemedicineHumansRegistriesTrasplante de corazónBalloon pumpPrimary graft failureRetrospective StudiesMechanical ventilationHeart transplantsSupervivenciabusiness.industryAnálisis de datosImmunosuppressionRetrospective cohort studyGeneral MedicineMiddle AgedSpainHeart retransplantationCardiologyHeart TransplantationHeart transplantbusiness
researchProduct

MicroRNAs in solid organ and vascularized composite allotransplantation: Potential biomarkers for diagnosis and therapeutic use

2020

Abstract Nowadays, solid organ transplantation (SOT) is an established treatment for patients with end-organ dysfunction, which dramatically improves the quality-of-life. Vascularized composite allotransplants (VCAs) including hand and face have been reported worldwide over the last 20 years. However, VCAs, differently to SOT, are life-enhancing instead of life-saving and are not routinely performed due to the risk of immune rejection and the adverse effects of immunosuppression. Over the past decade, although considerable improvements in short-term outcomes after allotransplantation have been registered, these results have not been translated into major progress in long-term allograft acce…

Graft Rejectionmedicine.medical_specialtyImmune rejectionmedicine.medical_treatmentBioinformaticsVascularized Composite AllotransplantationOrgan transplantationRNA interferencemicroRNABiomarker; Immune rejection; Micro-RNAs; Organ transplantation; Tolerance; Vascularized composite allotransplantationsmedicineHumansBiomarker discoveryVascularized composite allotransplantationsImmunosuppression TherapyVascularized Composite AllotransplantationTransplantationOrgan transplantationbusiness.industryMicro-RNAsImmunosuppressionBiomarkerBiomarker (cell)MicroRNAsVascularized composite allotransplantations Micro-RNAs Biomarker Immune rejection Organ transplantation TolerancebusinessToleranceBiomarkersAllotransplantation
researchProduct